<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 14, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093974</url>
  </required_header>
  <id_info>
    <org_study_id>Z7224L01</org_study_id>
    <nct_id>NCT03093974</nct_id>
  </id_info>
  <brief_title>Long Term Efficacy and Safety of Inhaled Colistimethate Sodium in Bronchiectasis Subjects With Chronic Pseudomonas Aeruginosa Infection.</brief_title>
  <acronym>PROMIS-I</acronym>
  <official_title>A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa (P. Aeruginosa)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zambon SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zambon SpA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to investigate the effect of the use of inhaled&#xD;
      colistimethate sodium, administered twice daily via the I-neb for 12 months, compared to&#xD;
      placebo in subjects with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with&#xD;
      P. aeruginosa on the frequency of pulmonary exacerbations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2017</start_date>
  <completion_date type="Actual">April 9, 2021</completion_date>
  <primary_completion_date type="Actual">April 9, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Pulmonary Exacerbation rate</measure>
    <time_frame>12 months</time_frame>
    <description>Annual mean NCFB pulmonary exacerbation rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first pulmonary exacerbation</measure>
    <time_frame>12 months</time_frame>
    <description>Time (in days) from the first dose of IMP until the first pulmonary exacerbation;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualised number of pulmonary exacerbation-free days</measure>
    <time_frame>12 months</time_frame>
    <description>Number of exacerbation-free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of severe NCFB pulmonary exacerbations,</measure>
    <time_frame>12 months</time_frame>
    <description>Severe NCFB pulmonary exacerbations are defined as those requiring intravenous antibiotics and/or hospitalisation;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first severe pulmonary exacerbation</measure>
    <time_frame>12 months</time_frame>
    <description>Time (in days) from first dose of IMP until the first severe pulmonary exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SGRQ)</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life (QoL) as measured by the total score of the Saint George's Respiratory Questionnaire (SGRQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL-B)</measure>
    <time_frame>12 months</time_frame>
    <description>change from baseline in total score Quality of Life - Bronchiectasis (QOL B) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of work absence</measure>
    <time_frame>12 months</time_frame>
    <description>Number of days of work absence due to NCFB pulmonary exacerbations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P. aeruginosa density</measure>
    <time_frame>12 months</time_frame>
    <description>the mean change in log10 colony forming units (CFU)/g sputum from baseline (Visit 2) to Day 28 of treatment (Visit 3) as well as to Visits 5 (6 months) to 7 (12 months), inclusive</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">377</enrollment>
  <condition>Non Cystic Fibrosis Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled colistimethate sodium twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>inhaled placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colistimethate Sodium</intervention_name>
    <description>1 M units equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <description>1 ml saline solution 0.45%</description>
    <arm_group_label>Saline solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. are able and willing to give informed consent, following a detailed explanation of&#xD;
             participation in the protocol and signed consent obtained;&#xD;
&#xD;
          2. aged 18 years or older of either gender;&#xD;
&#xD;
          3. diagnosed with NCFB by computerised tomography (CT) or high resolution CT (HRCT) as&#xD;
             recorded in the subject's notes and this is their predominant condition being treated;&#xD;
&#xD;
          4. had at least 2 NCFB pulmonary exacerbations requiring oral or inhaled antibiotics or 1&#xD;
             NCFB pulmonary exacerbation requiring intravenous antibiotics in the 12 months&#xD;
             preceding the Screening Visit (Visit 1) and had no NCFB pulmonary exacerbation with or&#xD;
             without treatment during the period between Visit 1 and Visit 2;&#xD;
&#xD;
          5. have a documented history of P. aeruginosa infection ;&#xD;
&#xD;
          6. are clinically stable and have not required a change in pulmonary treatment for at&#xD;
             least 30 days before the Screening Visit (Visit 1);&#xD;
&#xD;
          7. have pre-bronchodilator FEV1 ≥25% of predicted;&#xD;
&#xD;
          8. had a positive sputum culture for P. aeruginosa from an adequate sample taken at the&#xD;
             Screening Visit (Visit 1) or during the screening period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. known bronchiectasis as a consequence of cystic fibrosis (CF);&#xD;
&#xD;
          2. known history of hypogammaglobulinaemia requiring treatment with immunoglobulin,&#xD;
             unless fully replaced and considered immuno-competent by the Investigator;&#xD;
&#xD;
          3. myasthenia gravis or porphyria;&#xD;
&#xD;
          4. severe cardiovascular disease such as severe uncontrolled hypertension, ischaemic&#xD;
             heart disease or cardiac arrhythmia and any other conditions that would confound the&#xD;
             evaluation of safety, in the opinion of the Investigator;&#xD;
&#xD;
          5. had major surgery in the 3 months prior to Screening Visit (Visit 1) or planned&#xD;
             inpatient major surgery during the study period;&#xD;
&#xD;
          6. receiving treatment for allergic bronchopulmonary aspergillosis (ABPA);&#xD;
&#xD;
          7. had massive haemoptysis (greater than or equal to 300 mL or requiring blood&#xD;
             transfusion) in the preceding 4 weeks before Screening Visit (Visit 1) or between&#xD;
             Visit 1 and Visit 2;&#xD;
&#xD;
          8. respiratory failure that would compromise patient safety or confound the evaluation of&#xD;
             safety or efficacy of the study in the opinion of the Investigator;&#xD;
&#xD;
          9. current active malignancy, except for basal cell carcinoma or squamous cell carcinoma&#xD;
             of the skin without metastases;&#xD;
&#xD;
         10. taking immunosuppressive medications (such as azathioprine, cyclosporine, tacrolimus,&#xD;
             sirolimus, mycophenolate, rituximab), and/or anti-cytokine medications (such as anti&#xD;
             IL-6 and anti-tumour alpha necrosis factor products) in the preceding year before the&#xD;
             Screening Visit (Visit 1);&#xD;
&#xD;
         11. known history of human immunodeficiency virus (HIV);&#xD;
&#xD;
         12. current treatment for non-tuberculous mycobacterial (NTM) lung disease or&#xD;
             tuberculosis;&#xD;
&#xD;
         13. known or suspected to be allergic or unable to tolerate colistimethate sodium&#xD;
             (intravenous or inhaled) or other polymixins, including previous evidence of bronchial&#xD;
             hyperreactivity following inhaled colistimethate sodium;&#xD;
&#xD;
         14. treatment with long term (≥ 30 days) prednisone at a dose greater than 15 mg a day (or&#xD;
             equivalent dose of any other corticosteroid) within six months of the Screening Visit&#xD;
             (Visit 1)&#xD;
&#xD;
         15. new maintenance treatment with any oral macrolides (e.g.&#xD;
             azithromycin/erythromycin/clarithromycin) started within 30 days of the Screening&#xD;
             Visit (Visit 1) and between Visit 1 and Visit 2;&#xD;
&#xD;
         16. use of any intravenous or intramuscular or oral or inhaled antipseudomonal antibiotic&#xD;
             (except chronic oral macrolide treatment with a stable dose) within 30 days prior to&#xD;
             Screening Visit (Visit 1) and between Visit 1 and Visit 2;&#xD;
&#xD;
         17. pregnant or breast feeding or plan to become pregnant over the next year or of child&#xD;
             bearing potential and unwilling to use a reliable method of contraception for at least&#xD;
             one month before randomisation and throughout their involvement in the trial;&#xD;
&#xD;
         18. significant abnormality in clinical evaluations and/or laboratory tests (physical&#xD;
             examination, vital signs, haematology, clinical chemistry, clinically relevant&#xD;
             impaired renal function, defined as serum creatinine levels ≥2.0x upper limit of&#xD;
             normal, ECG) endangering the safe participation of the patient in the study at the&#xD;
             Screening Visit (Visit 1) and during the study;&#xD;
&#xD;
         19. participated in another investigational, interventional trial within 30 days prior to&#xD;
             the Screening Visit (Visit 1);&#xD;
&#xD;
         20. in the opinion of the Investigator not suitable for inclusion for whatever reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dearbhla Hull, MD</last_name>
    <role>Study Director</role>
    <affiliation>Zambon SpA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Chermside</city>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Concord</city>
        <zip>NSW 2134</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Frankston</city>
        <zip>VIC 3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Greenslopes</city>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Nedlands</city>
        <zip>WA 6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>New Lambton Heights</city>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>South Brisbane</city>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Spearwood</city>
        <zip>6163</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Westmead</city>
        <zip>NSW 2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22767</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>München</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>3436212</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Reẖovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Tsrifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Orbassano</city>
        <state>TO</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Brescia</city>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Foggia</city>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Palermo</city>
        <zip>90147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Auckland</city>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Dunedin</city>
        <zip>9016</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Hamilton West</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Aveiro</city>
        <zip>3814-501</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Braga</city>
        <zip>4710-243</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZambonInvestigative Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Guimarães</city>
        <zip>4835-044</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Loures</city>
        <zip>2674-514</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Vila Nova De Gaia</city>
        <zip>4435-502</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Torrejón de Ardoz</city>
        <zip>28850</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Usansolo</city>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Saint Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Cardiff</city>
        <zip>CF64 2XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative site</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EAH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Gillingham</city>
        <zip>ME7 5NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G31 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Kirkcaldy</city>
        <zip>KY2 5AH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigational site</name>
      <address>
        <city>Liverpool</city>
        <zip>L14 3PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Llanelli</city>
        <zip>SA14 8QF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SW36NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambon Investigative Site</name>
      <address>
        <city>Worcester</city>
        <zip>WR5 1DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

